Organization (Industry)
Fluidda (United States)
ClinicalTrials.gov lists Fluidda (United States) as lead sponsor of 13 trials. It has 1 approved asset.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 0 registered with a 2026 start date. The dashed outline is the pace from the 0 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 0.0 trial starts a year over the five years to September, under the 5 a year the method needs.
This page covers Fluidda (United States): 13 lead-sponsored trials and 2 legal-entity registrations.
Disease areas (6)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Pulmonary Disease, Chronic Obstructive | 6 |
| Asthma | 4 |
| Bronchiolitis | 3 |
| Bronchiolitis Obliterans Syndrome | 2 |
| Graft vs Host Disease | 2 |
Showing 5 of 6 disease areas.
Trials by start year as sponsor or collaborator (6)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2016 | 1 |
| 2015 | 5 |
| 2014 | 1 |
| 2013 | 1 |
| 2012 | 2 |
| 2011 | 5 |
Recruitment duration, a model prediction: none of the 13 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Approved assets (1)
| Drug | Trials |
|---|---|
| Roflumilast | 2 |
Journals published in (1)
| Journal | Publications |
|---|---|
| Expert review of respiratory medicine | 1 |
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 1 | 1 | 2025-11-18 |
Financing and grant events (3)
Shown in this order: most recent first.
| Date | Round type | Amount (USD) | Source |
|---|---|---|---|
| 2025-08-27 | NIH grant | 331,782 | Reporter |
| 2024-09-05 | NIH grant | 332,174 | Reporter |
| 2023-09-12 | NIH grant | 332,947 | Reporter |
Manufacturing and distribution sites (1)
| Facility | Location | Regulators | Member organization |
|---|---|---|---|
| FLUIDDA NV | Kontich Antwerpen, BE | FDA |
Latest dated events (19)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2025-11-18 | Patent granted | Granted US patents (PatentsView / USPTO) |
| 2025-08-27 | NIH grant | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
| 2024-09-05 | NIH grant | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
| 2023-09-12 | NIH grant | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
| 2016-12 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
Showing 5 of 19 events.
Biomarker capability evidence (3)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| CYP3A4 | Trial collaborator | Named in trial exclusion criteria |
| CFD | Trial collaborator | Mentioned in trial text |
| CYP3A4 | Trial collaborator | Mentioned in trial text |
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, active development programs, sponsor delivery record, sec-reported annual financials, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, climate targets, as filed, workforce and board diversity, as filed, organization relationships, clia clinical laboratory certificates, and biomarkers this organization publishes on.